Dr Grajales-Cruz on Real-World Teclistamab Data in BCMA-Pretreated Multiple Myeloma


In Partnership With:

Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.

Ariel Grajales-Cruz, MD, assistant member, Department of Malignant Hematology, Multiple Myeloma Section, Moffitt Cancer Center; assistant professor, University of South Florida, discusses the rationale for a real-world study of teclistamab-cqyv (Tecvayli) in patients with relapsed/refractory multiple myeloma who had received prior BCMA-directed therapy.

Bispecific antibodies are an evolving treatment option for patients with relapsed/refractory multiple myeloma, Grajales-Cruz says. Historically, after patients progressed on standard therapies, they did not have many treatment options, Grajales-Cruz notes. However, 3 bispecific antibodies are now approved by the FDA for patients with relapsed/refractory multiple myeloma. Teclistamab, a dual BCMA- and CD3-directed agent, was FDA approved in 2022 for patients with relapsed/refractory disease who have received 4 or more prior lines of therapy, including a proteasome inhibitor (PI) an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody. In August 2023, the FDA approved both the LAG-3 inhibitor elranatamab-bcmm (Elrexfio) and the GPRC5D-targeted bispecific antibody talquetamab-tgvs (Talvey) for this indication.

Findings from the single-arm, phase 2 MajesTEC-1 trial (NCT04557098), which investigated teclistamab in patients with relapsed/refractory multiple myeloma, supported the FDA approval of teclistamab. In this trial, teclistamab elicited an overall response rate of 61.8% (95% CI, 52.1%-70.9%) in patients with multiple myeloma who were relapsed/refractory to 3 or more prior therapies, including a PI, an IMiD, and an anti-CD38 monoclonal antibody (n = 110). Furthermore, at a median follow-up of 7.4 months, the estimated 9-month duration of response rate among responders was 66.5% (95% CI, 38.8%-83.9%).

However, the patient population in MajesTEC-1 did not include those with prior exposure to other BCMA-directed therapies, thus limiting oncologists’ ability to translate the data from MajesTEC-1 to the real-world setting, Grajales-Cruz explains. Variations in patient characteristics often exist between clinical trial populations and real-world populations, particularly in the community setting, Grajales-Cruz emphasizes. These population discrepancies prompted the evaluation of teclistamab in a real-world relapsed/refractory multiple myeloma population in comparison with the MajesTEC-1 population, Grajales-Cruz concluded.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD